Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALM001
MIFTS: 50

Al Amyloidosis

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Al Amyloidosis

About this section

MalaCards integrated aliases for Al Amyloidosis:

Name: Al Amyloidosis 52
Primary Systemic Amyloidosis 52 71
Primary Amyloidosis 52 71
Hereditary Amyloid Nephropathy Due to Lysozyme Variant 58
Familial Amyloid Nephropathy Due to Lysozyme Variant 58
Hereditary Renal Amyloidosis Due to Lysozyme Variant 58
Familial Renal Amyloidosis Due to Lysozyme Variant 58
Immunoglobulin Deposition Disease 71
Primary Systemic Al Amyloidosis 52
Amyloidosis Primary Systemic 52
Light Chain Amyloidosis 52
Primary Al Amyloidosis 52
Systemic Al Amyloidsis 52
Lysozyme Amyloidosis 58
Alys Amyloidosis 58
Amyloidosis Al 52

Characteristics:

Orphanet epidemiological data:

58
alys amyloidosis
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide);

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Metabolic diseases
Anatomical: Nephrological diseases Bone diseases Immune diseases Neuronal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare renal diseases
Rare systemic and rhumatological diseases


Sources

Summaries for Al Amyloidosis

About this section
NIH Rare Diseases : 52 AL amyloidosisis the most common form of amyloidosis, a group of disorders in which an abnormal protein called amyloid builds up in tissues and organs . The signs and symptoms of AL amyloidosis vary among patients because the build up may occur in the tongue, intestines, muscles, joints, nerves, skin, ligaments, heart, liver, spleen, or kidneys. To diagnose AL amyloidosis, healthcare professionals use blood or urine tests to identify signs of amyloid protein and a biopsy to confirm the diagnosis. Treatment may include chemotherapy directed at the abnormal plasma cells , stem cell transplantation , or other treatments based on which symptoms have developed.

MalaCards based summary : Al Amyloidosis, also known as primary systemic amyloidosis, is related to acute kidney failure and hereditary amyloidosis. An important gene associated with Al Amyloidosis is LYZ (Lysozyme). The drugs Ketamine and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and kidney, and related phenotypes are fatigue and hypertrophic cardiomyopathy

Wikipedia : 74 Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of... more...

Sources

Related Diseases for Al Amyloidosis

About this section

Diseases in the Amyloidosis family:

Al Amyloidosis Amyloidosis Aa
Hereditary Amyloidosis Primary Localized Amyloidosis
Ah Amyloidosis

Diseases related to Al Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 414, show less)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 30.0 B2M ADAMTS13
2 hereditary amyloidosis 30.0 LYZ B2M
3 intermittent claudication 29.7 VWF B2M
4 purpura 29.7 VWF ADAMTS13
5 amyloidosis, familial visceral 29.6 LYZ B2M
6 acquired von willebrand syndrome 29.5 VWF ADAMTS13
7 disseminated intravascular coagulation 29.4 VWF ADAMTS13
8 von willebrand's disease 29.2 VWF ADAMTS13
9 hydronephrosis 29.2 VWF B2M
10 hemorrhagic disease 29.2 VWF ADAMTS13
11 portal hypertension 29.1 VWF ADAMTS13
12 hemangioma 28.7 VWF ACTC1
13 myeloma, multiple 11.9
14 primary localized amyloidosis 11.7
15 light chain deposition disease 11.4
16 amyloidosis 11.3
17 amyloidosis, primary localized cutaneous, 1 11.2
18 amyloidosis, primary localized cutaneous, 2 11.2
19 amyloidosis, primary localized cutaneous, 3 11.2
20 amyloidosis, hereditary, transthyretin-related 11.1
21 plasma cell neoplasm 10.7
22 nephrotic syndrome 10.6
23 congestive heart failure 10.4
24 amyloidosis aa 10.4
25 macroglossia 10.4
26 factor x deficiency 10.4
27 monoclonal gammopathy of uncertain significance 10.3
28 neuropathy 10.3
29 end stage renal disease 10.3
30 macroglobulinemia 10.3
31 kidney disease 10.3
32 polyneuropathy 10.3
33 myopathy 10.3
34 peripheral nervous system disease 10.3
35 carpal tunnel syndrome 10.3
36 pure autonomic failure 10.3
37 cholestasis 10.2
38 plasmacytoma 10.2
39 hypertrophic cardiomyopathy 10.2
40 restrictive cardiomyopathy 10.2
41 diarrhea 10.2
42 autonomic neuropathy 10.1
43 constipation 10.1
44 interstitial nephritis 10.1
45 lymphoplasmacytic lymphoma 10.1
46 colitis 10.1
47 intestinal pseudo-obstruction 10.1
48 glomerulonephritis 10.1
49 systemic scleroderma 10.1
50 atrial standstill 1 10.0
51 autoimmune disease 10.0
52 lymphoma, hodgkin, classic 10.0
53 lymphoma, non-hodgkin, familial 10.0
54 exanthem 10.0
55 lymphoma 10.0
56 lymphoproliferative syndrome 10.0
57 mucositis 10.0
58 toxic shock syndrome 10.0
59 hypothyroidism 10.0
60 thrombocytopenia 10.0
61 arthropathy 10.0
62 b-cell lymphoma 10.0
63 chronic kidney disease 10.0
64 herpes zoster 10.0
65 vasculitis 10.0
66 pulmonary embolism 10.0
67 splenomegaly 10.0
68 dysphagia 10.0
69 syncope 10.0
70 acute liver failure 10.0
71 blood protein disease 10.0 VWF B2M
72 graft-versus-host disease 10.0
73 diastolic heart failure 10.0
74 hypereosinophilic syndrome 10.0
75 chromosomal triplication 10.0
76 engraftment syndrome 10.0
77 heavy chain deposition disease 10.0
78 transitional cell carcinoma 10.0
79 systemic lupus erythematosus 9.9
80 rheumatoid arthritis 9.9
81 temporal arteritis 9.9
82 thrombophilia due to thrombin defect 9.9
83 ocular motor apraxia 9.9
84 budd-chiari syndrome 9.9
85 marginal zone b-cell lymphoma 9.9
86 collagenous colitis 9.9
87 cardiac arrest 9.9
88 heart disease 9.9
89 goiter 9.9
90 neutropenia 9.9
91 hepatic coma 9.9
92 dilated cardiomyopathy 9.9
93 poems syndrome 9.9
94 hepatitis c 9.9
95 sensory peripheral neuropathy 9.9
96 extramedullary plasmacytoma 9.9
97 amyloid tumor 9.9
98 active peptic ulcer disease 9.9
99 ileus 9.9
100 arthritis 9.9
101 ulcerative colitis 9.9
102 cholangitis 9.9
103 smoldering myeloma 9.9
104 hypoglycemia 9.9
105 autonomic dysfunction 9.9
106 constrictive pericarditis 9.9
107 pericarditis 9.9
108 bilirubin metabolic disorder 9.9
109 cutis laxa 9.9
110 cutis verticis gyrata 9.9
111 acquired cutis laxa 9.9
112 keratoconjunctivitis sicca 9.9
113 keratoconjunctivitis 9.9
114 amyloid neuropathy 9.9
115 pulmonary sarcoidosis 9.9
116 renal cell carcinoma, nonpapillary 9.9
117 inclusion body myositis 9.9
118 myositis 9.9
119 greig cephalopolysyndactyly syndrome 9.9
120 sarcoidosis 1 9.9
121 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
122 nonarteritic anterior ischemic optic neuropathy 9.9
123 pseudoxanthoma elasticum 9.9
124 fabry disease 9.9
125 diabetes and deafness, maternally inherited 9.9
126 muscle hypertrophy 9.9
127 myelodysplastic syndrome 9.9
128 mantle cell lymphoma 9.9
129 sleep apnea 9.9
130 diffuse alopecia areata 9.9
131 charcot-marie-tooth disease 9.9
132 protein-losing enteropathy 9.9
133 tooth disease 9.9
134 respiratory failure 9.9
135 cardiac tamponade 9.9
136 radial neuropathy 9.9
137 bronchopneumonia 9.9
138 gout 9.9
139 sick sinus syndrome 9.9
140 facial paralysis 9.9
141 optic nerve disease 9.9
142 cryoglobulinemia 9.9
143 pustulosis of palm and sole 9.9
144 liver cirrhosis 9.9
145 severe combined immunodeficiency 9.9
146 progressive multifocal leukoencephalopathy 9.9
147 connective tissue disease 9.9
148 psoriasis 9.9
149 chronic dacryoadenitis 9.9
150 dacryoadenitis 9.9
151 alopecia 9.9
152 chronic graft versus host disease 9.9
153 fibrillary glomerulonephritis 9.9
154 multifocal motor neuropathy 9.9
155 primary orthostatic hypotension 9.9
156 undifferentiated connective tissue disease 9.9
157 raynaud phenomenon 9.9
158 dysautonomia 9.9
159 wild type attr amyloidosis 9.9
160 light and heavy chain deposition disease 9.9
161 overgrowth syndrome 9.9
162 thyroid carcinoma 9.9
163 cystadenocarcinoma 9.8 B2M ACTC1
164 uremia 9.8 VWF B2M
165 kaposi sarcoma 9.8
166 angina pectoris 9.8
167 thrombosis 9.8
168 hereditary lymphedema i 9.8
169 chronic myelomonocytic leukemia 9.8
170 hyperparathyroidism 9.8
171 peritonitis 9.8
172 diffuse alveolar hemorrhage 9.8
173 thrombotic microangiopathy 9.8 VWF ADAMTS13
174 colorectal cancer 5 9.8 VWF ADAMTS13
175 bladder cancer 9.8
176 cardiac arrhythmia 9.8
177 cardiac conduction defect 9.8
178 diabetes insipidus, nephrogenic, autosomal 9.8
179 amyotrophy, hereditary neuralgic 9.8
180 celiac disease 1 9.8
181 familial mediterranean fever 9.8
182 sjogren syndrome 9.8
183 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.8
184 ventricular fibrillation, paroxysmal familial, 1 9.8
185 niemann-pick disease, type b 9.8
186 anxiety 9.8
187 myocardial infarction 9.8
188 hepatitis c virus 9.8
189 lung cancer susceptibility 3 9.8
190 leukemia, acute lymphoblastic 9.8
191 gaucher disease, type i 9.8
192 factor vii deficiency 9.8
193 factor v deficiency 9.8
194 volvulus of midgut 9.8
195 retinal detachment 9.8
196 leukemia, chronic lymphocytic 9.8
197 intussusception 9.8
198 hypercholesterolemia, familial, 1 9.8
199 lymphoma, mucosa-associated lymphoid type 9.8
200 leukemia, acute lymphoblastic 3 9.8
201 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
202 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
203 imerslund-grasbeck syndrome 2 9.8
204 deficiency anemia 9.8
205 pulmonary hypertension 9.8
206 aspiration pneumonia 9.8
207 hypophosphatemia 9.8
208 adult t-cell leukemia 9.8
209 inflammatory bowel disease 9.8
210 diffuse large b-cell lymphoma 9.8
211 secondary progressive multiple sclerosis 9.8
212 atrioventricular block 9.8
213 follicular lymphoma 9.8
214 ischemic colitis 9.8
215 atrial fibrillation 9.8
216 ptosis 9.8
217 waldenstroem's macroglobulinemia 9.8
218 bone disease 9.8
219 covid-19 9.8
220 amyotrophic neuralgia 9.8
221 microinvasive gastric cancer 9.8
222 gastric ulcer 9.8
223 lipoid nephrosis 9.8
224 brucellosis 9.8
225 microcytic anemia 9.8
226 megacolon 9.8
227 pulmonary edema 9.8
228 hemopericardium 9.8
229 mitral valve insufficiency 9.8
230 iron deficiency anemia 9.8
231 pericardial effusion 9.8
232 hepatorenal syndrome 9.8
233 gastroparesis 9.8
234 graves' disease 9.8
235 leukemia 9.8
236 vulva cancer 9.8
237 hepatitis a 9.8
238 acute leukemia 9.8
239 guillain-barre syndrome 9.8
240 focal segmental glomerulosclerosis 9.8
241 crescentic glomerulonephritis 9.8
242 obstructive jaundice 9.8
243 suppurative cholangitis 9.8
244 capillary leak syndrome 9.8
245 niemann-pick disease 9.8
246 pneumothorax 9.8
247 toxic megacolon 9.8
248 epilepsy 9.8
249 gaucher's disease 9.8
250 rectum cancer 9.8
251 vulva squamous cell carcinoma 9.8
252 motor neuron disease 9.8
253 monoclonal paraproteinemia 9.8
254 iron metabolism disease 9.8
255 thrombophilia 9.8
256 agammaglobulinemia 9.8
257 hairy cell leukemia 9.8
258 hypersensitivity reaction type iv disease 9.8
259 severe acute respiratory syndrome 9.8
260 papillary carcinoma 9.8
261 scleredema adultorum 9.8
262 lysosomal storage disease 9.8
263 central nervous system disease 9.8
264 breast disease 9.8
265 cranial nerve palsy 9.8
266 gastritis 9.8
267 liver disease 9.8
268 rapidly progressive glomerulonephritis 9.8
269 lymphopenia 9.8
270 prion disease 9.8
271 adenoma 9.8
272 t-cell lymphoblastic leukemia/lymphoma 9.8
273 hyperthyroidism 9.8
274 intestinal obstruction 9.8
275 lung disease 9.8
276 monocytic leukemia 9.8
277 nervous system disease 9.8
278 duodenitis 9.8
279 hypopituitarism 9.8
280 diabetes insipidus 9.8
281 episodic ataxia 9.8
282 systolic heart failure 9.8
283 carotenemia 9.8
284 47,xyy 9.8
285 homologous wasting disease 9.8
286 leukemia, t-cell, chronic 9.8
287 polymyositis 9.8
288 remitting seronegative symmetrical synovitis with pitting edema 9.8
289 scleromyxedema 9.8
290 cytomegalovirus infection 9.8
291 head injury 9.8
292 headache 9.8
293 paresthesia 9.8
294 posttransplant acute limbic encephalitis 9.8
295 rare systemic disease 9.8
296 rare hemorrhagic disorder 9.8
297 alect2 amyloidosis 9.8
298 ah amyloidosis 9.8
299 cardiogenic shock 9.8
300 afib amyloidosis 9.8
301 bombay phenotype 9.8 VWF ADAMTS13
302 splenic sequestration 9.8 VWF ADAMTS13
303 hypertensive retinopathy 9.8 VWF ADAMTS13
304 senile plaque formation 9.8
305 kearns-sayre syndrome 9.8
306 stroke, ischemic 9.8
307 progressive familial heart block, type ib 9.8
308 porphyria cutanea tarda 9.8
309 mastocytosis, cutaneous 9.8
310 progressive familial heart block, type ia 9.8
311 arteries, anomalies of 9.8
312 hyperlipoproteinemia, type iii 9.8
313 lipoprotein quantitative trait locus 9.8
314 tongue squamous cell carcinoma 9.8
315 bone resorption disease 9.8
316 xerophthalmia 9.8
317 hemiplegia 9.8
318 esophagitis 9.8
319 pancytopenia 9.8
320 right bundle branch block 9.8
321 porphyria 9.8
322 urticaria 9.8
323 duodenal ulcer 9.8
324 cholecystitis 9.8
325 polycythemia 9.8
326 paralytic ileus 9.8
327 amyloidosis beta2m 9.8
328 von willebrand disease, type 2 9.8 VWF ADAMTS13
329 von willebrand disease, type 3 9.8 VWF ADAMTS13
330 angiodysplasia 9.8 VWF ADAMTS13
331 primary thrombocytopenia 9.7 VWF ADAMTS13
332 autoimmune disease of cardiovascular system 9.7 VWF ADAMTS13
333 malignant hypertension 9.7 VWF ADAMTS13
334 inherited blood coagulation disease 9.7 VWF ADAMTS13
335 blood coagulation disease 9.7 VWF ADAMTS13
336 thrombotic thrombocytopenic purpura 9.7 VWF ADAMTS13
337 coronary stenosis 9.7 VWF ADAMTS13
338 hemolytic uremic syndrome, atypical 1 9.7 VWF ADAMTS13
339 myelofibrosis 9.7
340 helicobacter pylori infection 9.7
341 dermatitis herpetiformis, familial 9.7
342 intraocular pressure quantitative trait locus 9.7
343 antithrombin iii deficiency 9.7
344 chondrosarcoma 9.7
345 anemia, autoimmune hemolytic 9.7
346 amyloidosis of gingiva and conjunctiva, with mental retardation 9.7
347 varicose veins 9.7
348 pulmonary hypertension, primary, 1 9.7
349 endosteal hyperostosis, autosomal dominant 9.7
350 hashimoto thyroiditis 9.7
351 colorectal cancer 9.7
352 breast cancer 9.7
353 amyotrophic lateral sclerosis 1 9.7
354 fanconi renotubular syndrome 2 9.7
355 gastric cancer 9.7
356 multinodular goiter 9.7
357 chronic neutrophilic leukemia 9.7
358 osteonecrosis 9.7
359 cholelithiasis 9.7
360 fanconi syndrome 9.7
361 hypertrophy of breast 9.7
362 sarcoma 9.7
363 esophageal varix 9.7
364 primary hyperparathyroidism 9.7
365 mononeuropathy 9.7
366 ureteral benign neoplasm 9.7
367 primary biliary cirrhosis 9.7
368 pure red-cell aplasia 9.7
369 acute cholangitis 9.7
370 neuritis 9.7
371 impotence 9.7
372 hepatitis b 9.7
373 lateral sclerosis 9.7
374 colon adenocarcinoma 9.7
375 macrocytic anemia 9.7
376 iga glomerulonephritis 9.7
377 adenocarcinoma 9.7
378 interstitial lung disease 9.7
379 rhabdomyosarcoma 9.7
380 ischemia 9.7
381 bladder disease 9.7
382 thrombophlebitis 9.7
383 heart valve disease 9.7
384 hyperglycemia 9.7
385 spindle cell sarcoma 9.7
386 tubular adenocarcinoma 9.7
387 chronic inflammatory demyelinating polyradiculoneuropathy 9.7
388 demyelinating polyneuropathy 9.7
389 subvalvular aortic stenosis 9.7
390 hemolytic anemia 9.7
391 paraplegia 9.7
392 compartment syndrome 9.7
393 thyroiditis 9.7
394 axonal neuropathy 9.7
395 hemarthrosis 9.7
396 dermatitis herpetiformis 9.7
397 crohn's disease 9.7
398 orbital disease 9.7
399 exophthalmos 9.7
400 osteosclerotic myeloma 9.7
401 tenosynovitis 9.7
402 myotonic dystrophy 9.7
403 48,xyyy 9.7
404 laryngocele 9.7
405 back pain 9.7
406 hypotonia 9.7
407 plasma cell tumor 9.7
408 refractory anemia 9.7
409 red cell aplasia 9.7
410 antiphospholipid syndrome 9.6 VWF ADAMTS13
411 hemolytic-uremic syndrome 9.6 VWF ADAMTS13
412 blood platelet disease 9.6 VWF ADAMTS13
413 patent foramen ovale 9.5 VWF ACTC1
414 hellp syndrome 9.5 VWF ADAMTS13

Graphical network of the top 20 diseases related to Al Amyloidosis:



Diseases related to Al Amyloidosis
Sources

Symptoms & Phenotypes for Al Amyloidosis

About this section

Human phenotypes related to Al Amyloidosis:

31 (showing 53, show less)
# Description HPO Frequency HPO Source Accession
1 fatigue 31 hallmark (90%) HP:0012378
2 hypertrophic cardiomyopathy 31 hallmark (90%) HP:0001639
3 hepatomegaly 31 frequent (33%) HP:0002240
4 proteinuria 31 frequent (33%) HP:0000093
5 nephropathy 31 frequent (33%) HP:0000112
6 renal insufficiency 31 frequent (33%) HP:0000083
7 dyspnea 31 frequent (33%) HP:0002094
8 arthralgia 31 frequent (33%) HP:0002829
9 congestive heart failure 31 frequent (33%) HP:0001635
10 nephrotic syndrome 31 frequent (33%) HP:0000100
11 enlarged kidney 31 frequent (33%) HP:0000105
12 lymphadenopathy 31 frequent (33%) HP:0002716
13 pedal edema 31 frequent (33%) HP:0010741
14 abnormality of chromosome segregation 31 frequent (33%) HP:0002916
15 interstitial pulmonary abnormality 31 frequent (33%) HP:0006530
16 pulmonary edema 31 frequent (33%) HP:0100598
17 multiple myeloma 31 frequent (33%) HP:0006775
18 monoclonal immunoglobulin m proteinemia 31 frequent (33%) HP:0005508
19 arthropathy 31 frequent (33%) HP:0003040
20 abnormal ekg 31 frequent (33%) HP:0003115
21 elevated alkaline phosphatase 31 frequent (33%) HP:0003155
22 chronic constipation 31 frequent (33%) HP:0012450
23 acute infectious pneumonia 31 frequent (33%) HP:0011949
24 macroglossia 31 occasional (7.5%) HP:0000158
25 malabsorption 31 occasional (7.5%) HP:0002024
26 abnormal blistering of the skin 31 occasional (7.5%) HP:0008066
27 papule 31 occasional (7.5%) HP:0200034
28 hepatitis 31 occasional (7.5%) HP:0012115
29 xerostomia 31 occasional (7.5%) HP:0000217
30 hematuria 31 occasional (7.5%) HP:0000790
31 gastrointestinal hemorrhage 31 occasional (7.5%) HP:0002239
32 hypertension 31 occasional (7.5%) HP:0000822
33 purpura 31 occasional (7.5%) HP:0000979
34 osteoarthritis 31 occasional (7.5%) HP:0002758
35 goiter 31 occasional (7.5%) HP:0000853
36 keratoconjunctivitis sicca 31 occasional (7.5%) HP:0001097
37 abnormality of bone marrow cell morphology 31 occasional (7.5%) HP:0005561
38 asplenia 31 occasional (7.5%) HP:0001746
39 pleural effusion 31 occasional (7.5%) HP:0002202
40 upper airway obstruction 31 occasional (7.5%) HP:0002781
41 polyneuropathy 31 occasional (7.5%) HP:0001271
42 aortic root aneurysm 31 occasional (7.5%) HP:0002616
43 orthostatic hypotension due to autonomic dysfunction 31 occasional (7.5%) HP:0004926
44 adrenal insufficiency 31 occasional (7.5%) HP:0000846
45 skin nodule 31 occasional (7.5%) HP:0200036
46 intermittent claudication 31 occasional (7.5%) HP:0004417
47 bradycardia 31 occasional (7.5%) HP:0001662
48 autonomic bladder dysfunction 31 occasional (7.5%) HP:0005341
49 abnormality of the submandibular glands 31 occasional (7.5%) HP:0010287
50 mechanical ileus 31 occasional (7.5%) HP:0010676
51 plasmacytoma 31 occasional (7.5%) HP:0011857
52 jaw claudication 31 occasional (7.5%) HP:0030164
53 decreased circulating antibody level 31 occasional (7.5%) HP:0004313

MGI Mouse Phenotypes related to Al Amyloidosis:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.02 ACTC1 ADAMTS13 B2M LYZ VWF
Sources

Drugs & Therapeutics for Al Amyloidosis

About this section

Drugs for Al Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 225, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4
Ondansetron Approved Phase 3 99614-02-5 4595
5
Dalteparin Approved Phase 3 9005-49-6
6
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
7
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
8
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
11
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
12
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
13
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
14
Lenalidomide Approved Phase 3 191732-72-6 216326
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
18
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
19
Daratumumab Approved Phase 3 945721-28-8
20
Ixazomib Approved, Investigational Phase 3 1072833-77-2
21
Lenograstim Approved, Investigational Phase 3 135968-09-1
22
Melphalan Approved Phase 3 148-82-3 460612 4053
23
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
24
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
25
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Molgramostim Investigational Phase 3 99283-10-0
28 Anesthetics, Dissociative Phase 3
29 Hormones Phase 3
30 Anti-Infective Agents Phase 3
31 Anti-Bacterial Agents Phase 3
32 Antiparasitic Agents Phase 3
33 Antiprotozoal Agents Phase 3
34 Dermatologic Agents Phase 3
35 Neurotransmitter Agents Phase 3
36 Analgesics Phase 3
37 Liver Extracts Phase 3
38 Antifungal Agents Phase 3
39 Anti-Anxiety Agents Phase 3
40 Psychotropic Drugs Phase 3
41 Antipsychotic Agents Phase 3
42 Fibrinolytic Agents Phase 3
43 Heparin, Low-Molecular-Weight Phase 3
44 Excitatory Amino Acid Antagonists Phase 3
45 Narcotics Phase 3
46 Analgesics, Opioid Phase 3
47 Cola Phase 3
48 Hematinics Phase 3
49 Epoetin alfa Phase 3 113427-24-0
50 Anesthetics Phase 3
51 Anesthetics, General Phase 3
52 Anesthetics, Intravenous Phase 3
53 ferric gluconate Phase 3
54 Iron Supplement Phase 3
55 Amebicides Phase 3
56 Liposomal amphotericin B Phase 3
57 Gastrointestinal Agents Phase 3
58 Antineoplastic Agents, Hormonal Phase 3
59 Antiemetics Phase 3
60 Hormone Antagonists Phase 3
61 glucocorticoids Phase 3
62 Anti-Inflammatory Agents Phase 3
63 Antirheumatic Agents Phase 3
64 Immunologic Factors Phase 3
65 Alkylating Agents Phase 3
66 Immunosuppressive Agents Phase 3
67 Antibodies, Monoclonal Phase 3
68 Adjuvants, Immunologic Phase 3
69 Immunoglobulin G Phase 3
70
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
71
Mesna Approved, Investigational Phase 2 3375-50-6 598
72
Pomalidomide Approved Phase 2 19171-19-8
73
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
74
Silicon Approved, Investigational Phase 2 7440-21-3 4082203
75
Busulfan Approved, Investigational Phase 2 55-98-1 2478
76
Carmustine Approved, Investigational Phase 2 154-93-8 2578
77
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
78
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
79
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
80
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
81
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
82
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
83
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
84
Methotrexate Approved Phase 1, Phase 2 59-05-2, 1959-05-2 126941
85
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
86
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
87
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
88
Elotuzumab Approved Phase 2 915296-00-3
89
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
90
Gliclazide Approved Phase 2 21187-98-4 3475
91 Siltuximab Approved, Investigational Phase 2 541502-14-1
92
Etoposide Approved Phase 2 33419-42-0 36462
93
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
94
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
95
Etanercept Approved, Investigational Phase 2 185243-69-0
96
Amiodarone Approved, Investigational Phase 2 1951-25-3 2157
97
Idelalisib Approved Phase 2 870281-82-6
98
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
99
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
100
Epicatechin Investigational Phase 2 490-46-0, 35323-91-2 72276
101
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
102
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
103 Antibiotics, Antitubercular Phase 1, Phase 2
104 interferons Phase 2
105 Interferon-alpha Phase 2
106 Rho(D) Immune Globulin Phase 1, Phase 2
107 gamma-Globulins Phase 1, Phase 2
108 Bendamustine Hydrochloride Phase 2
109 Trace Elements Phase 2
110 Antioxidants Phase 2
111 Neuroprotective Agents Phase 2
112 Nutrients Phase 2
113 Micronutrients Phase 2
114 Anti-Retroviral Agents Phase 2
115 Antitubercular Agents Phase 1, Phase 2
116 Cyclosporins Phase 1, Phase 2
117 Calcineurin Inhibitors Phase 1, Phase 2
118 Antimetabolites Phase 2
119 Antilymphocyte Serum Phase 2
120 Anti-HIV Agents Phase 2
121 Interleukin-2 Phase 2
122 Anti-Asthmatic Agents Phase 1, Phase 2
123
Beclomethasone Phase 1, Phase 2 4419-39-0 20469
124 Tubulin Modulators Phase 1, Phase 2
125
Isophosphamide mustard Phase 1, Phase 2 0
126 Antimitotic Agents Phase 1, Phase 2
127 Mitogens Phase 1, Phase 2
128 Interleukin-4 Phase 1, Phase 2
129 Anticonvulsants Phase 1, Phase 2
130 polysaccharide-K Phase 1, Phase 2
131 N-monoacetylcystine Phase 1, Phase 2
132 Angiogenesis Inhibitors Phase 2
133 Dexamethasone 21-phosphate Phase 2
134 Etoposide phosphate Phase 2
135
Liposomal doxorubicin Phase 2 31703
136 Analgesics, Non-Narcotic Phase 2
137 Anti-Inflammatory Agents, Non-Steroidal Phase 2
138 Myeloma Proteins Phase 2
139 Paraproteins Phase 2
140 Adrenergic beta-Antagonists Phase 2
141 Sodium Channel Blockers Phase 2
142 Vasodilator Agents Phase 2
143 Anti-Arrhythmia Agents Phase 2
144 diuretics Phase 2
145 Potassium Channel Blockers Phase 2
146 Diuretics, Potassium Sparing Phase 2
147 Cytochrome P-450 CYP3A Inhibitors Phase 2
148 Immunoglobulin M Phase 2
149
carbamide peroxide Approved Phase 1 124-43-6
150
Sunitinib Approved, Investigational Phase 1 557795-19-4, 341031-54-7 5329102
151
Tacrolimus Approved, Investigational Phase 1 104987-11-3 445643 439492 6473866
152
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
153
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
154
Methylprednisolone Approved, Vet_approved Phase 1 83-43-2 6741
155
Prednisolone phosphate Approved, Vet_approved Phase 1 302-25-0
156
Methylprednisolone hemisuccinate Approved Phase 1 2921-57-5